DC
ELVN icon

Diametric Capital’s Enliven Therapeutics ELVN Stock Holding History

Diametric Capital’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-29,284
Closed -$515K – 401
2024
Q1 		$515K Buy
+29,284
New +$449K 0.29% 79
2023
Q1 		– Sell
-42,986
Closed -$703K – 378
2022
Q4 		$703K Buy
+42,986
New +$687K 0.34% 108

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Diametric Capital's ELVN Position: Q2 2024 in Review

Diametric Capital sold out of Enliven Therapeutics (ELVN) in Q2 2024, closing a stake of 29,284 shares — an estimated $515K sold.

Diametric Capital first reported a position in ELVN in Q4 2022 and held it in 2 quarters. The position peaked at $703K in Q4 2022. 93 funds tracked by Wall St. Rank hold ELVN as of Q2 2024.

  • Diametric Capital reported no remaining Enliven Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Diametric Capital sold 29,284 Enliven Therapeutics shares in Q2 2024, an estimated $515K.
  • Diametric Capital first reported a position in Enliven Therapeutics in Q4 2022 and held it in 2 quarters.
  • Diametric Capital's Enliven Therapeutics position peaked at $703K in Q4 2022.
  • 93 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2024.

Based on Diametric Capital's 13F filing for Q2 2024, filed 13 Aug 2024.